405089-28-3

Usage

Uses

Used in Pharmaceutical Research and Development:
Ethanone, 1-[1-(2-methoxyphenyl)cyclobutyl]-2-[3-[[4-(trifluoromethyl)phenoxy]methyl]-1-piperidinyl]is employed as a compound of interest in pharmaceutical research and development. Its unique structure and potential applications in the medical field make it a valuable target for the exploration of new treatments for various conditions.
Used in Medical Field Applications:
In the medical field, Ethanone, 1-[1-(2-methoxyphenyl)cyclobutyl]-2-[3-[[4-(trifluoromethyl)phenoxy]methyl]-1-piperidinyl]is used as a potential treatment for a variety of conditions. Its precise structural components and the possibility of interacting with biological targets make it a promising candidate for the development of new therapeutic agents.

Upstream product

• 405066-36-6 2-chloro-1-[1-(2-methoxy-phenyl)-cyclobutyl]-ethanone 
• 405063-22-1 3-(4-trifluoromethyl-phenoxymethyl)-piperidine 

Downstream Products

• 405089-29-4 1-[1-(2-methoxy-phenyl)-cyclobutyl]-2-[3-(4-trifluoromethyl-phenoxymethyl)-piperidin-1-yl]-ethanol 

Relevant academic research and scientific papers

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.